U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549



FORM 10-QSB



QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934



FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2006



COMMISSION FILE NO. 0-28413



HUMAN BIOSYSTEMS

(Exact name of small business issuer as specified in its charter)



CALIFORNIA                                                                           77-0481056

(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)



1127 HARKER AVENUE

PALO ALTO, CALIFORNIA 94301

(Address of principal executive offices)



650-323-0943

(Issuer's telephone number)



Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X]   No [ ]



Indicate by check mark whether the registrant is a shell company (as defined in Rule 12(b)-2 of the Exchange Act) Yes [ ]   No [X]



At June 30, 2006, the registrant had 71,864,100 outstanding shares of common stock, no par value.



Transitional Small Business disclosure format:  Yes [ ]   No  [X]



============================================================================



2

HUMAN BIOSYSTEMS

FORM 10-QSB

TABLE OF CONTENTS



PAGE

PART I - FINANCIAL INFORMATION



ITEM 1.  FINANCIAL STATEMENTS



CONDENSED BALANCE SHEET (UNAUDITED) -- as of June 30, 2006..........................F-1



CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

For the Three Months Ended June 30, 2006 and 2005 and the Six Months

Ended June 30, 2006 and 2005 and the Period from February 26, 1998

(Inception) through June 30, 2006........................................................F-2



CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT (UNAUDITED)

For the Six Months Ended June 30, 2006.........................................................................F-3



CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

For the Six Months Ended June 30, 2006 and 2005,

and the Period from February 26, 1998 (Inception) through June 30, 2006........................F-4



NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)....................F-5-11



ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS

OR PLAN OF OPERATION.....................................................................................4



ITEM 3.  CONTROLS AND PROCEDURES.........................................................................16



PART II - OTHER INFORMATION......................................................................................16



ITEM 1.  LEGAL PROCEEDINGS..........................................................................................16



ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES

AND USE OF PROCEEDS......................................................................................16



ITEM 3.  DEFAULTS UPON SENIOR SECURITIES..........................................................17



ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.........17



ITEM 5.  OTHER INFORMATION.......................................................................................17



ITEM 6.  EXHIBITS ...............................................................................................................17



SIGNATURES ........................................................................................................................17

============================================================================

3

ITEM 1.  FINANCIAL STATEMENTS.



[bs01002.gif]



F-1



[so01002.gif]



F-2



[se01002.gif]



F-3



[cf01002.gif]



F-4

HUMAN BIOSYSTEMS

(A DEVELOPMENT STAGE COMPANY)

NOTES TO CONDENSED FINANCIAL STATEMENTS

(UNAUDITED)

1. BASIS OF PRESENTATION

Human BioSystems (hereinafter referred to as the "Company") is a development stage company incorporated on February 26, 1998 under the laws of the State of California. The business purpose of the Company is to develop the technology for preservation of certain biologic material, including platelets (a blood component), red blood cells, heart valves, tissue and organs. The Company is in the ninth year of its research and development activities. The Company's goal is to develop the technology to extend and maintain functionality of these materials for much longer periods of time than is currently possible.

The accompanying unaudited condensed financial statements have been prepared in accordance with Securities and Exchange Commission requirements for interim financial statements. Therefore, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. The financial statements should be read in conjunction with the Company's Form 10-KSB for the year ended December 31, 2005.

The interim financial statements present the condensed balance sheet, statements of operations, stockholders' deficit and cash flows of Human BioSystems. The financial statements have been prepared in accordance with accounting principles generally accepted in the United States.

The interim financial information is unaudited. In the opinion of management, all adjustments necessary to present fairly the financial position of the Company as of June 30, 2006 and the results of operations and cash flows presented herein have been included in the financial statements. Interim results are not necessarily indicative of results of operations for the full year.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.



2. STOCK COMPENSATION

On January 1, 2006 the Company adopted Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004), Share-Based Payment, requiring the Company to recognize expense related to the fair value of its employee stock option awards. The Company recognizes the cost of all share-based awards on a graded vesting basis over the vesting period of the award. Total stock compensation expense recognized by the Company during the three months and six months ended June 30, 2006 was $30,700 and $52,600, respectively.

Prior to January 1, 2006, the Company accounted for its stock option plans under the recognition and measurement provisions of APB Opinion No. 25, Accounting for Stock Issued to Employees, and related Interpretations, as permitted by SFAS No. 123, Accounting for Stock-Based Compensation.  Effective January 1, 2006, the Company adopted the fair value recognition provisions of SFAS No. 123(R), using the modified-prospective-transition method. Under that transition method, compensation cost recognized in 2006 includes: (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, and (b) compensation cost for all share-based payments granted subsequent to January 1,
2006, based on the grant-date fair value estimated in accordance with the provisions of SFAS No. 123(R). Results for prior periods have not been restated.

As a result of adopting SFAS 123(R) on January 1, 2006, the Companys income before income taxes and net income for the three months and six months ended June 30, 2006, was $10,400 and $4,000 lower, respectively, than if the Company had continued to account for share-based compensation under Opinion 25. Basic and diluted earnings per share for the three months and six months ended June 30, 2006 would have both been $(.01) if the Company had not adopted SFAS No. 123(R).

F-5

Prior to the adoption of SFAS No. 123(R), the Company presented all tax benefits of deductions resulting from the exercise of stock options as operating cash flows in the Statement of Cash Flows. Beginning on January 1, 2006, the Company changed its cash flow presentation in accordance with SFAS No. 123(R), which requires the cash flows resulting from the tax benefits resulting from tax deductions in excess of the compensation cost recognized for those options (excess tax benefits) to be classified as financing cash flows.

The Company has estimated the fair value of its option awards granted after January 1, 2006 using a modified Black-Scholes option valuation model that uses the assumptions noted in the following table. Expected volatilities are based on the historical volatility of the Companys stock. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of options granted is derived from the output of the option valuation model and represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

|                                                           |        
|---------------------------------------------------------- | -------
|                                                           |        
|Modified Black-Scholes -Based Option Valuation Assumptions | 2006   
|Fair value of options granted during the period            | $26,000
|Expected term (in years)                                   | 3.2    
|Expected volatility                                        | 226%   
|Weighted average volatility                                | 226%   
|Expected dividend yield                                    | 0.0%   
|Risk-free rate                                             | 4.64%  

The Company estimated the fair value of its option awards granted prior to January 1, 2006 using the Black-Scholes option-pricing formula. The Black-Scholes option pricing model was used with the following weighted-average assumptions for grants made in the following years:

|                                                |      |  |      |         |      |   |         |  |   |        | 
|----------------------------------------------- | ---- |  | ---- | ------- | ---- | - | ------- |  | - | ------ | 
|Black-Scholes Option Valuation Assumptions      | 2005 |  | 2004 |         | 2003 |  
|Fair value of options granted during the period |      |  | $    | 196,003 |      | $ | 125,942 |  | $ | 34,214 | 
|Expected term (in years)                        |      |  |      | 1.8     |      |   | 3.0     |  |   | 1.0    | 
|Expected volatility                             |      |  |      | 205%    |      |   | 244%    |  |   | 236%   | 
|Expected dividend yield                         |      |  |      | 0.0%    |      |   | 0.0%    |  |   | 0.0%   | 
|Risk free rate                                  |      |  |      | 3.9%    |      |   | 2.2%    |  |   | 1.6%   | 

The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of SFAS 123 Accounting for Stock-Based Compensation, to options granted under the Companys stock option plans during the three month and six month periods ended June 30, 2005. For purposes of this pro forma disclosure, the value of the options is amortized to expense on a graded vesting basis over a three year vesting period and forfeitures are recognized as they occur.



F-6



|                                                                          |                                  |                                |   |            
|------------------------------------------------------------------------- | -------------------------------- | ------------------------------ | - | -----------
|                                                                          | Three months ended June 30, 2005 | Six months ended June 30, 2005
|Net loss, as reported                                                     | $                                | (1,658,800)                    | $ | (2,022,400)
|Total stock-based employee compensation expense determined under          |                                  |                                |   |            
|fair value based method for all option awards, net of related tax effects |                                  | (6,200)                        |   | (15,600)   
|                                                                          |                                  |                                |   |            
|Pro forma net income                                                      | $                                | (1,665,000)                    | $ | (2,038,000)
|                                                                          |                                  |                                |   |            
|Basic earnings per share as reported                                      | $                                | (.03)                          | $ | (.04)      
|Basic earnings per share pro forma                                        | $                                | (.03)                          | $ | (.04)      
|Diluted earnings per share as reported                                    | $                                | (.03)                          | $ | (.04)      
|Diluted earnings per share pro forma                                      | $                                | (.03)                          | $ | (.04)      

The following table summarizes the stock option transactions for the six months ended June 30, 2006:

|                               |           |  |                      |  |                         
|------------------------------ | --------- |  | -------------------- |  | ------------------------
|Stock Options                  | Shares    |  | WeightedAveragePrice |  | AggregateIntrinsic Value
|Outstanding at January 1, 2006 | 1,324,000 |  | $0.36                |  | $ 6,200                 
|Granted                        | 100,000   |  | $0.23                |  | -                       
|Exercised                      | -         |  | -                    |  | -                       
|Forfeited                      | 125,000   |  | -                    |  | -                       
|                               |           |  |                      |  |                         
|Outstanding at June 30, 2006   | 1,299,000 |  | $0.35                |  | $ 6,200                 
|                               |           |  |                      |  |                         
|Exercisable at June 30, 2006   | 986,000   |  | $0.35                |  | $ 6,200                 
|                               |           |  |                      |  |                         



F-7

The aggregate intrinsic value of options exercised during the six months ended June 30, 2006 and June 30, 2005 was zero.



3. INVESTMENT IN MARKETABLE SECURITIES



Cost and fair value of marketable securities as of June 30, 2006 are as follows:



[note3002.gif]



4. OTHER LIABILITIES



Other liabilities as of June 30, 2006 consist of $226,100 of deposits from investors for which the Company owes 500,000 shares of common stock.



5. PUBLIC RELATIONS AGREEMENTS



During March 2005, and subsequently amended during April 2005, the Company entered into an agreement with a public relations and promotions services company for consulting services. The public relations and promotions services company will promote the Company to the investment community and the general public through press releases and other communications, all of which must be approved in advance by the Company. The term of the agreement is 6 months, subject to prior termination. In consideration of the services being performed, the Company will issue compensation shares equal to 30% of the increase in buy volume of the Company's common stock directly attributable to the public relations and promotions services company, as defined in the agreement. The Company will also issue bonus shares of 10% of the increase in buy volume of the Company's common stock in the event the sales price of the Company's common stock equals or exceeds $0.25 per share. Additionally, the Company has agreed to issue 7.0 million shares of common stock to be held by an escrow agent.



During June 2005, the Company entered into a second agreement with the public relations and promotions services company for additional consulting services in exchange for 750,000 shares of the Company's common stock valued at $247,500. The Company issued the shares in June 2005.



During November 2005, the Company entered into a third agreement with the public relations and promotions services company for additional consulting services in exchange for 500,000 shares of the Company's common stock valued at $345,000. The Company issued the shares in November 2005.



Through December 31, 2005 the Company released 4,963,600 shares of common stock totaling $3,125,200 in consideration of these agreements. Additionally, the Company recorded a public relations payable for approximately 219,400 additional compensation and bonus shares to be released at a future date valued at $187,900. During the three months ended March 31, 2006, 201,100 shares valued at $134,200 were released in satisfaction of this payable. No shares were released during the three months ended June 30, 2006.

F-8

6. DUE TO STOCKHOLDERS



Stockholder payables consist of the following as of June 30, 2006:



Wages payable to stockholder employees

$88,700



Accrued vacation for stockholder employees

10,000



$98,700



7. NOTES PAYABLE



In November 2005, the Company entered into a finance agreement for payment of its D&O insurance. The agreement calls for monthly payments of approximately $6,800 per month through August 2006. The balance payable as of June 30, 2006 was $13,300. Prepaid expenses as of June 30, 2006 includes $25,400 pertaining to the D&O insurance.



In March 2006, the Company entered into a loan agreement with an independent lender.  The lender agreed to loan the Company an amount based on 50% of the value of a portfolio of 500,000 shares of the Companys common stock (approximately $75,000).  These shares are held as collateral only. The lender will receive a loan fee equal to five percent of the gross loan proceeds (approximately $3,700). The conversion feature related to the note payable was recorded as a discount of $75,000 and $7,300 of this discount was accreted during the six months ended June 30, 2006. The agreement calls for interest payment of 4.99% annual rate of the loan amount payable quarterly for period three years. At maturity, the Company has the option to pay off the loan balance and receive the same number of shares pledged, sell the pledged shares under certain conditions or renew the loan under certain conditions, or forfeit the shares and not repay the loan.



8. COMMON STOCK



In January 2006, the Company entered into an addendum to a consulting agreement with a consultant for the sale of common stock in Europe pursuant to a trustee arrangement.  The Company agreed to pay the consultant a commission equal to three percent of the proceeds from the sale of such shares.



On January 26, 2006, the Securities and Exchange Commission declared effective the Companys Registration Statement on Form SB-2 (File No. 33-128991), registering an aggregate of 20,000,000 shares of the Companys common stock for sale to the public.  The Company intends to use the stock for raising capital, but to date has not entered into any arrangements for any such financing.



In February 2006, the Company entered into an extension of an agreement signed in 2003 with the above-referenced consultant for services including the coordination of investor relations in Europe.  In consideration for such extension, the Company issued to the consultant an aggregate of 100,000 free trading shares and 200,000 restricted shares of common stock valued at $126,000.



In March 2006, the Company entered into a Securities Purchase Agreement (the Agreement) with La Jolla Cove Investors, Inc., a California corporation (La Jolla Cove).  Pursuant to the Agreement, La Jolla Cove agreed to purchase from the Company a 63⁄4% Convertible Debenture in the aggregate principal amount of $30,000 (the Debenture).  Pursuant to the agreement terms, the Company received $30,000, the purchase price of the debenture.



In connection with the Debenture, the Company issued to La Jolla Cove a Warrant to Purchase Common Stock (the Warrant), dated as of March 7, 2006, to purchase an aggregate of 3,000,000 shares of common stock.  Pursuant to the terms of the Warrant, the Company received $95,000 as a prepayment towards the future exercise of Warrant Shares.



In May 2006, the Company returned to La Jolla Cove the aggregate advances of $125,000.  Management believed that due to substantially modified terms proposed for the transaction by La Jolla Cove, the parties failed to agree on the material terms and conditions of this proposed transaction.  The Company and La Jolla Cove subsequently mutually agreed not to pursue this transaction.



In the first quarter of 2006, the Company entered into agreements with various consultants for investor relations and investor awareness services in the United States and Europe.  The Company paid for such services with a combination of $29,000 in cash, and 245,400 shares of free trading common stock valued at $82,000.



In the first quarter of 2006, the Company issued 12,800 shares of restricted common stock and 12,800 shares of free trading common stock valued at $10,000 for public relations payable.

F-9

In the first quarter of 2006, the Company issued 125,900 shares of restricted common stock and 125,900 shares of free trading common stock valued at $90,000 for services related to public relations.



In the second quarter of 2006, the Company entered into agreements with various consultants for investor relations and investor awareness services in the United States and Europe.  The Company paid for such
services with a combination of $29,000 in cash, and 613,600 shares of free trading common stock valued at $157,800.



In the second quarter of 2006, the Company issued 159,500 shares of restricted common stock and 159,500 shares of free trading common stock, valued at $83,200, for services related to public relations.



In the second quarter of 2006, the Company issued 17,700 shares of restricted common stock in satisfaction of accounts payable, valued at $5,300.



9. INVESTMENT AGREEMENT



In June 2004, the Company entered into an Investment Agreement (the "Investment Agreement") with Dutchess Private Equities Fund II, LP ("Dutchess") effective June 28, 2004. Pursuant to the terms of the Investment Agreement, the Company may offer, through a series of puts, and Dutchess must purchase up to 38,000,000 shares of the Company's common stock with an aggregate purchase price up to $5,000,000. The purchase price of the shares is equal to 95% of the lowest closing "best bid" price (the highest posted bid price) during the five trading days immediately following the date of put. The value that the Company will be permitted to put pursuant to the Investment Agreement will be either: (A) 200% of the average daily volume in the US market of the common stock for the ten trading days prior to the notice of put multiplied by the average of the three daily closing bid prices immediately preceding the date of the put, or (B) $10,000. No single put can exceed $1,000,000.  Pursuant to the Investment Agreement, Dutchess acquired a total of 434,615 shares of the Company's common stock, for approximately $297,500, during the year ended December 31, 2005, and 886,000 shares, for approximately $260,200, during the six months ended June 30, 2006.



F-10

10. GOING CONCERN



Going concern - The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company is in the development stage, has no operating revenue and incurred a net loss of approximately $1,355,500 for the six months ended June 30, 2006. The Company is in the ninth year of research and development, with an accumulated loss during the development stage of approximately $21,820,600. As of June 30, 2006, management is uncertain as to the completion date or if the product will be completed at all.



These conditions give rise to substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company's continuation as a going concern is dependent upon its ability to obtain additional financing or sale of its common stock as may be required and ultimately to attain profitability.



Management's plan, in this regard, is to raise financing of approximately $2,500,000 through a combination of equity and debt financing. Management believes this amount will be sufficient to finance the continuing research for the next twelve months. However, there is no assurance that the Company will be successful in raising such financing.  In 2005, in furtherance of its capital raising goals, the Company entered into an agreement with a financial advisor and placement agent for assistance with structuring, issuance and sale of the Companys securities.



11. SUBSEQUENT EVENTS



During July 2006, pursuant to the investment agreement described in Note 9 above, the Company issued an aggregate of 624,971 shares of its common stock for approximately $105,000 in total consideration.



During July 2006, the Company also entered into agreements with various consultants for investor relations and investor awareness services. The Company paid for such services with a combination of $13,000 in cash, and an aggregate of 645,925 shares of free trading common stock valued at $85,231, and 45,925 shares of restricted common stock valued at $6,231.



During July 2006, the Company issued an aggregate of 40,000 shares of restricted common stock to one investor for $5,200 in cash.



On July 19, 2006, the Company signed a letter of intent (LOI) to acquire two ethanol production facility projects from EXL III Group Corporation (EXL III), an equity partner in ethanol plant ventures.  The Company will also enlist the services of Claude Luster III, the principal of EXL III, to serve as the president of a new subsidiary to be formed to develop the ethanol business.  The LOI provides that the Company will acquire the projects from EXL III for shares of restricted common stock.  In addition, the Company will enter into a Consulting Services Agreement with Mr. Luster.



During July 2006, the Company issued 100,000 shares of restricted common stock for cancellation of debt.



During August 2006, the Company issued an aggregate of 892,857 shares of restricted stock to two individuals for total cash consideration of $125,000.



During August 2006, the Company resolved its disagreement with La Jolla Cove Investors.  The parties executed a settlement agreement with mutual releases, and the Company paid $1,500 in cash to La Jolla Cove Investors.



F-11

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.



THIS QUARTERLY REPORT CONTAINS FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, INCLUDING, WITHOUT LIMITATION, STATEMENTS REGARDING OUR EXPECTATIONS, BELIEFS, INTENTIONS OR FUTURE STRATEGIES THAT ARE SIGNIFIED BY THE WORDS "EXPECTS," "ANTICIPATES," "INTENDS," "BELIEVES," OR SIMILAR LANGUAGE.  THESE FORWARD-LOOKING STATEMENTS INVOLVE RISKS, UNCERTAINTIES AND OTHER FACTORS.  ALL FORWARD-LOOKING STATEMENTS INCLUDED IN THIS DOCUMENT ARE BASED ON INFORMATION AVAILABLE TO US ON THE DATE HEREOF AND SPEAK ONLY AS OF THE DATE HEREOF.  THE FACTORS DISCUSSED BELOW UNDER "RISK FACTORS" AND ELSEWHERE IN THIS QUARTERLY REPORT ON FORM 10-QSB ARE AMONG THOSE FACTORS THAT IN SOME CASES HAVE AFFECTED OUR RESULTS AND COULD CAUSE THE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS.



The following discussion should be read in conjunction with the Condensed Financial Statements and Notes thereto.



Overview/ Recent Developments



We are a developmental stage company, and have a very limited operating history and no revenue to date.  Our prospects must be considered in light of the risks and uncertainties encountered by companies in an early stage of development involving new technologies and overcoming regulatory approval process requirements before any revenue is possible.



We have experienced operating losses since our inception.  These losses have resulted from the significant costs incurred in the development of our technology and the establishment of our research and development facility. Expenditures will increase in all areas in order to execute our business plan, particularly in research and development and in gaining regulatory approval to market our products in the U.S. and abroad.



In 2003, we experienced increased difficulty in raising outside capital.  This difficulty continued through the third quarter of 2004.  Although research continued in organ preservation, we were forced to suspend animal testing and human infusion testing due to a lack of funds.  Our employees accepted a temporary 50% salary reduction in January 2004 to conserve cash, and several of these employees as well as certain of our outside consultants elected to convert a portion of their deferred compensation to shares of our common stock.  On September 1, 2004, we restored all employee salaries; however, employees received 50% of their salaries in cash and 50% in shares of restricted common stock. In February 2005, we changed our overall compensation structure to reduce recurring payroll expenses in non- critical areas in order to provide additional resources for the completion of our scientific objectives.  In March 2005, we made the decision to pay all of the accrued salaries in cash rather than in stock.



During the six-month period ended June 30, 2005, we pursued various alternatives for raising capital, including but not limited to transactions with Dutchess, Langley Park Investments PLC ("Langley") and Pini Ben David ("Ben David"). In October 2005, we entered into an agreement with Ascendiant Capital to assist in the capital-raising process, and in March 2006, we entered into a loan transaction and received approximately $71,000 in net proceeds (see "Liquidity and Capital Resources" below for detailed descriptions of all of the above transactions).  We also have continued to raise funds through the sales of our capital stock through Regulation S under the Securities Act.  To date, we continue to seek alternative sources for capital.



We are a developer of preservation platforms for organs and other biomaterial, specializing in the development of proprietary above zero (HBS-AZ) and below zero (HBS-BZ) organ and tissue preservation
systems and methods for preserving blood platelets.  We have been successful in preserving blood platelets for ten days under refrigeration while maintaining cell structure and morphology, which has never been done before to our knowledge.  We had originally contemplated submitting our findings to the FDA in the first half of 2003; however, additional pre-human infusion tests were necessary to address certain aspects of our findings. We believe that we have now satisfactorily resolved all issues raised by these findings, and resumed our human infusion tests in February 2005.  Some delays have been encountered at the centers conducting the tests, as it was necessary for the centers to repeat our in-vitro (test tube) tests prior to proceeding to the actual human tests. Internal approval for starting the pre-human infusion studies had to be secured, which is now in place.  Additional approvals to commence human in-vivo studies will be required from the internal review board and possibly from the FDA.  We currently anticipate that these tests will be completed within the next four to six months.



We began research on kidney preservation in 2002 and have developed what we believe is a solution that will operate under refrigerated temperature storage conditions for over 30 hours, allowing organ preservation beyond current capabilities. In our most recent preliminary tests, we successfully transplanted a rat kidney that had been frozen at a temperature of negative 80 degrees Centigrade for three months in our patent-pending HBS sub-zero solution. In October 2005, we successfully completed the initial phase of our survival studies of animals with transplanted kidneys preserved using our HBS organ preservation solution, and were able to preserve a rat's kidney at negative 196 degrees Centigrade for up to five days while maintaining some functionality when transplanted back into the animal, evidenced by urine production. We previously preserved rats' kidneys at negative 20 and negative 80 degrees Centigrade. We will continue to conduct further tests on a larger animal sample size, and conduct histology and survival studies as well. Our goal is to extend the kidney shelf life for up to 72 to 96 hours at above freezing temperatures and even longer at sub-zero temperatures.  We believe that the extended shelf life should enable better matching of donor kidneys to recipients. In the third quarter of 2005, we also purchased a special freezer and equipment used to conduct experiments at negative 80 degrees Centigrade.  Recent survival studies on animals with kidneys stored in the HBS-AZ solution for 14 days showed an 83% survival rate versus 42% and 10% for the respective UW and HTK (European) solutions.  Further recent studies using biochemical test markers have corroborated these studies.  In 2006, we intend to seek opportunities to license our organ preservation technology for storage at temperatures above zero degrees Centigrade.



4

In July 2002, we received our first patent on our technology and methodology for preserving blood platelets.  We filed a provisional patent application in June 2001 to cover our improved platelet preservation methods. In August 2003, we filed another patent application covering improved platelet preservation methods.   In May 2006, the U.S. Patent Office approved our patent for organ preservation entitled "Methods and Solutions for Storing Donor Organs" U.S. Patent No. 7,029,839, and in August 2006 we were granted our fourth patent, U.S. Patent No. 7,083,910, entitled Preservation of Blood Platelets with Citrate. We will seek strategic alliances with companies that have the capability to provide technical and clinical expertise as well as financial and marketing expertise to leverage our current expertise in these areas.



In addition to our attempts to raise outside capital, we have pursued opportunities to acquire existing products and businesses that currently produce, or have the potential to produce, revenue.  In July 2006, we signed a letter of intent to acquire options to purchase two parcels of real estate, upon which we intend to develop two ethanol production facilities, from EXL III Group Corporation (EXL II), an equity partner in ethanol plant ventures.  The LOI provides that we will acquire the options from EXL III for restricted common stock.  We will also enter into a consulting services agreement with Claude Luster III, the principal of EXL III, who will serve as the president of a new subsidiary to be formed to develop the ethanol business.  The purpose of the acquisition is to generate revenues on a predictable timetable while our blood platelet preservation technology is awaiting human infusion tests.   Consummation of the acquisition and the consulting agreement is dependent upon a number of conditions precedent, including but not limited to acquiring the required financing, due diligence and negotiation of definitive agreements.

Results of Operations



THREE MONTHS ENDED JUNE 30, 2006 COMPARED WITH THREE MONTHS ENDED JUNE 30, 2005



Revenues.  We did not generate any revenue in either of the three-month periods ended June 30, 2006 or 2005, and we have not generated revenues since our inception in February 1998, as our focus to date has been on the research and development of products.  We are a development stage company in the ninth year of research and development activities, and do not anticipate receiving revenue until we complete product development and clinical testing.



General and Administrative Expenses.   Total general and administrative expenses in the three months ended June 30, 2006 were $635,500, a decrease from $1,605,900 for the three months ended June 30, 2005.  The decrease was due primarily to a significant decrease in public relations expenses to $270,000 for the three months ended June 30, 2006. We had public relations expenses of $1,118,300 for the comparable period in 2005. The public relations expenses for the three months ended June 30, 2006, resulted from public relations agreements with several consultants pursuant to which we provided cash and common stock as payment for public relations services. We valued the stock at fair market value on the date of issuance or as specified in the agreement.



We experienced an increase in stock-based compensation in the three months ended June 30, 2006 to



$30,700, from $6,200 for the three months ended June 30, 2005. From time to time, our staff has worked for under market rate compensation or has had to accrue pay for extended periods of time when financing was not available.  We have granted stock options to certain employees in partial consideration for salary reductions, and certain employees have elected to receive stock in lieu of compensation.   For the foreseeable future, we anticipate that we will continue to issue stock-based incentives in the form of stock grants and/or options and warrants to employees and key consultants to retain the services of such key personnel during this crucial period when we are preparing submissions to the FDA to conduct human studies for platelets and to expand our organ preservation development effort.  We will also utilize non-cash compensation to retain the services of key personnel if we consummate definitive agreements with EXL for the ethanol projects described above.



We experienced a decrease in other general and administrative expenses to $334,800 for the three months ended June 30, 2006, from $481,400 for the comparable period in 2005.  This decrease was due to decreases in legal and professional fees and other expenses.



Research and Development.  Our research and development expenses were $32,500 for the three months ended June 30, 2006, a slight decrease from $52,100 for the comparable period in 2005.    This decrease was primarily due to our attempts to moderate research and development spending.  While we have resumed our infusion studies and organ preservation research, we believe that recent reduced payroll reductions have allowed us to maintain our scientific program to this point.  We are now preparing to accelerate our development efforts, utilizing our freezing technology, into cells as well as to continue with organs.  This will require additional research facility space in Michigan, which we anticipate will result in increased expenses in the future.  We have also recently formed a committee and have enlisted the services of an outside veterinarian to oversee our organ preservation experiments using animals.



Sales and Marketing Expenses.  We had no sales and marketing expenses for the respective three month periods ended June 30, 2006 or 2005. We recently eliminated payroll in the sales and marketing area in order to give priority to the completion of our scientific objectives  to complete human infusion studies for platelets and move closer to human testing utilizing our organ preservation technology.



Other Income and Expense.  We incurred interest expense of $9,900 during the three months ended June 30, 2006, due primarily to interest on certain accounts payable. We did not incur interest expense during the comparable period in 2005.



5

Net Loss.  As a result of the foregoing factors, our net loss decreased to $677,900 for the three months ended June 30, 2006, from a net loss of $1,658,800 for the three months ended June 30, 2005. We had an unrealized loss of $27,600 on our investment in Langley securities during the three months ended June 30, 2005, resulting in a total comprehensive loss of $1,686,400 for the period.  Our net loss per share was $0.01 for the three months ended June 30, 2006, a decrease from $0.03 for the comparable period in 2005.



SIX MONTHS ENDED JUNE 30, 2006 COMPARED WITH SIX MONTHS ENDED JUNE 30, 2005



Revenues.  We did not generate any revenue in either of the six-month periods ended June 30, 2006 or 2005, and we have not generated revenues since our inception in February 1998, as our focus to date has been on the research and development of products.  We are a development stage company in the ninth year of research and development activities, and do not anticipate receiving revenue until we complete product development and clinical testing.



General and Administrative Expenses.   Total general and administrative expenses in the six months ended June 30, 2006 were $1,275,600, a decrease from $1,899,400 for the six months ended June 30, 2005.  The decrease was due primarily to a significant decrease in public relations expenses to $597,100 for the six months ended June 30, 2006. We had public relations expenses of $1,118,300 for the comparable period in 2005. The public relations expenses for the six months ended June 30, 2006, resulted from public relations agreements with several consultants pursuant to which we provided cash and common stock as payment for public relations services. We valued the stock at fair market value on the date of issuance or as specified in the agreements. During the six months ended June 30, 2006, we also released 201,100 shares valued at $134,200 in satisfaction of a payable from an agreement with Abernathy Mendelson & Associates (Abernathy) pursuant to which we provide shares of common stock as payment for advertising and promotional services.



We experienced an increase in stock-based compensation in the six months ended June 30, 2006 to $52,600, from $38,800 for the six months ended June 30, 2005. From time to time, our staff has worked for under market rate compensation or has had to accrue pay for extended periods of time when financing was not available.  We have granted stock options to certain employees in partial consideration for salary reductions, and certain employees have elected to receive stock in lieu of compensation.   For the foreseeable future, we anticipate that we will continue to issue stock-based incentives in the form of stock grants and/or options and warrants to employees and key consultants to retain the services of such key personnel during this crucial period when we are preparing submissions to the FDA to conduct human studies for platelets and to expand our organ preservation development effort.  We will also utilize non-cash compensation to retain the services of key personnel if we consummate definitive agreements with EXL for the ethanol projects described above.



We experienced a decrease in other general and administrative expenses to $625,900 for the six months ended June 30, 2006, from $742,300 for the comparable period in 2005.  This decrease was due to decreases in legal and professional fees and other expenses.



Research and Development.  Our research and development expenses were $74,500 for the six months ended June 30, 2006, a slight decrease from $96,000 for the comparable period in 2005.    This decrease was primarily due to our attempts to moderate research and development spending.  While we have resumed our infusion studies and organ preservation research, we believe that recent reduced payroll reductions have allowed us to maintain our scientific program to this point.   We are now preparing to accelerate our development efforts, utilizing our freezing technology, into cells as well as to continue with organs.  This will require additional research facility space in Michigan, which we anticipate will result in increased expenses in the future.  We have also recently formed a committee and have enlisted the services of an outside veterinarian to oversee our organ preservation experiments using animals.



6

Sales and Marketing Expenses.  We had no sales and marketing expenses for the six months ended June 30, 2006, a decrease from $25,400 for the comparable period in 2005. We recently eliminated payroll in the sales and marketing area in order to give priority to the completion of our scientific objectives  to complete human infusion studies for platelets and move closer to human testing utilizing our organ preservation technology.



Other Income and Expense.  We incurred interest expense of $12,000 during the six months ended June 30, 2006, due primarily to interest on certain accounts payable. We did not incur interest expense during the comparable period in 2005.   We also recognized $6,600 in the six months ended June 30, 2006 from the forgiveness of debt on an account payable converted to stock.



Net Loss.  As a result of the foregoing factors, our net loss decreased to $1,355,500 for the six months ended June 30, 2006, from a net loss of $2,022,400 for the six months ended June 30, 2005. We had an unrealized loss of $3,200 on our investment in Langley securities during the six months ended June 30, 2006, resulting in a total comprehensive loss of $1,358,700 for the period.  In the six months ended June 30, 2005, we had an unrealized loss of $27,200 on our investment in Langley securities, resulting in a total comprehensive loss of $2,049,600.  Our net loss per share was $0.02 for the six months ended June 30, 2006, a decrease of $0.04 for the comparable period in 2005.



Liquidity and Capital Resources



Our operating plan for calendar year 2006 is focused on continued development of our products. It is our estimate that a cash requirement of $2.5 million is required to support this plan for the next twelve months. During the six-month period ended June 30, 2006, we received an aggregate of $724,400 from the issuance of common stock and $75,000 from borrowing on notes payable, compared to an aggregate of $552,700 received from the issuance of common stock in the six-month period ended June 30, 2005.  We are actively seeking additional funding. Once we receive the required additional financing, we anticipate continued growth in our operations and a corresponding growth in our operating expenses and capital expenditures. We do not anticipate any revenue from operations for the next two or three years. Therefore, our success will be dependent on funding from private placements of equity securities. Although we have entered into certain agreements with Dutchess, Ascendiant and Strategic Growth Ventures (see below) there can be no assurance that we will be successful in raising any capital pursuant to any of these agreements. At the present time, we have no other agreements or arrangements for any private placements.



In 2003, we experienced increased difficulty in raising outside capital.  This difficulty continued through the third quarter of 2004.  Although research continued in organ preservation, we were forced to suspend animal testing and human infusion testing due to a lack of funds.  Our employees accepted a temporary 50% salary reduction in January 2004 to conserve cash, and several of these employees as well as certain of our outside consultants elected to convert a portion of their deferred compensation to shares of our common stock. On September 1, 2004, we restored all employee salaries; however, employees received 50% of their salaries in cash and 50% in shares of restricted common stock. In February 2005, we changed our overall compensation structure to reduce recurring payroll expenses in non-critical areas in order to provide additional resources for the completion of our scientific objectives. In March 2005, we made the decision to pay all of the accrued salaries in cash rather than in stock.



We are in the ninth year of research and development, with an accumulated loss during the development stage of $21,820,600.  As of June 30, 2006, we are uncertain as to the completion date of our research and development, or if products will ever be completed as a result of this research and development activity.  We anticipate that the funds spent on research and development activities will need to increase prior to completion of a product. Additionally, we may not be able to secure funding in the future necessary to complete our intended research and development activities.



In addition, we have recently entered into a letter of intent to acquire options to purchase two parcels of real estate, upon which we intend to develop two ethanol production facilities.  The completion of these
facilities, if the options are acquired, exercised and developed, will require significant additional capital.  We currently anticipate that we will require approximately $2 million to prepare the sites and obtain the necessary permits to commence construction of the two ethanol plants.  Additional long-term financing will be required to complete the construction of the facilities and to make them operational, currently estimated to be $150 million per 100 million gallon production capacity facility.  At the present time, we do not have the requisite capital, and have not entered into any agreements or understandings for such long-term financing.



These conditions give rise to substantial doubt about our ability to continue as a going concern. Our financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should we be unable to continue as a going concern.  Our continuation as a going concern is dependent upon our ability to obtain additional financing from the sale of our common stock, as may be required, and ultimately to attain profitability.  The report of our independent certified public accountants, included in this prospectus, contains a paragraph regarding our ability to continue as a going concern.



During the six-month period ended June 30, 2006, we continued to spend cash to fund our operations. Cash used by operating activities for the six-month period ended June 30, 2006 equaled $662,900 and consisted principally of our net loss of $1,355,500 plus decreases of $4,100 in accrued liabilities and $3,400 in other assets, offset by decreases of $30,900 in prepaid expenses, $539,100 in public relations expenses paid or to be paid in common stock, $52,600 provided by stock-based compensation, decreases of $68,700 in accounts payable, $7,300 in amortization of discount and loan fees on notes payable, and $1,500 in depreciation.  For 2005, cash used by operating activities equaled $450,900, and consisted of our net loss of $2,022,400 plus increases of $4,000 in prepaid expenses and decreases of $3,800 in accrued liabilities, offset by $282,500 in stock-based compensation, $1,118,200 in public relations expenses paid or to be paid from common stock, $700 in depreciation, increases of $2,900 in accounts payable, and $175,000 in other liabilities.



We did not utilize or receive cash from investment activities during the respective six months ended June 30, 2006, compared to a use of $11,000 for the comparable period in 2005 due to the purchase of fixed assets.



7

Cash flows from financing activities for the six-month period ended June 30, 2006 produced a net increase in cash of $692,600, consisting of $724,400 from the issuance of common stock and $75,000 from borrowing on notes payable, offset by $39,400 of principal payments on a note payable for directors and officers insurance and a decrease of $67,400 in amounts due to shareholders.   In the six months ended June 30, 2005, we had a net increase in cash of $416,700 from financing activities, comprised of $552,700 in proceeds from the issuance of common stock, offset by a decrease of $136,000 in amounts due to shareholders.



As of June 30, 2006, we had cash and cash equivalents amounting to $71,300, a decrease from the balance of $233,500 at June 30, 2005.  Our working capital deficit decreased to $639,600 at June 30, 2006, from $844,300 at June 30, 2005.  There were no material commitments for capital expenditures at June 30, 2006.

During 2005 and 2006, we pursued various alternatives for raising capital. We entered into an Investment Agreement (the "Investment Agreement") with Dutchess effective June 28, 2004.  Pursuant to the terms of the Investment Agreement, we may offer, through a series of puts, and Dutchess must purchase from time to time, up to a maximum of 38,000,000 shares of our common stock, provided that Dutchess shall not be required to purchase shares of our stock with an aggregate purchase price in excess of $5,000,000.  The purchase price of shares purchased under the Investment Agreement shall be equal to 95% of the lowest closing "best bid" price (the highest posted bid price) of the common stock during the five consecutive trading days immediately following the date of our notice to Dutchess of our election to put shares pursuant to the Investment Agreement. The dollar value that we will be permitted to put pursuant to the Investment Agreement will be either: (A) 200% of the average daily volume in the US market of the common stock for the ten trading days prior to the notice of our put, multiplied by the average of the three daily closing bid prices immediately preceding the date of the put, or (B) $10,000.  No single put can exceed $1,000,000. We filed a registration statement on Form SB-2 in July 2004 to register for resale an aggregate of 38,000,000 shares of common stock issuable under the Investment Agreement; this registration statement was declared effective on August 23, 2004. Through June 30, 2006, we have issued an aggregate of 1,320,646 shares of common stock to Dutchess, for aggregate net proceeds of $556,620.  We intend to exercise additional puts under the Investment Agreement in the last half of 2006 to provide funding for our operations.



In July 2004, we entered into a Stock Purchase Agreement (the "Stock Purchase Agreement"), whereby we would sell shares of our restricted common stock for shares in Langley, a London-based institutional investment trust.  Langley was formed in February 2004 to invest in a diverse portfolio of U.S. small-cap companies (defined by Langley management as those public companies having a market capitalization of less than U.K. $100 million). Although Langley's investments are not limited to specific sectors, it has concentrated on mining, oil and gas, energy-related and technology companies since it commenced operations in February 2004. Langley's stated investment objective is to achieve long-term capital growth. The Langley ordinary shares are registered as a unit investment trust on the London Stock Exchange ("LSE"). The trading symbol for the ordinary shares is LSE:LPI. The Langley Investment Trust consists of a portfolio of the common stock of 23 U.S. publicly traded small cap companies.



Langley purchased 7,000,000 shares of our restricted stock at a price of $910,000, or approximately $0.13 per share.  The shares issued to Langley constituted 17.9% of our outstanding common stock at July 31, 2004.  In lieu of cash, Langley issued to us an aggregate of 512,665 Langley ordinary shares at a price of U.K. $1.00 per share (one British Pound Sterling = US $1.8160 on July 30, 2004).  The Langley ordinary shares issued to us constituted less than one percent of Langley's issued and outstanding ordinary shares at September 30, 2004.  The total sales price of $910,000 was determined by multiplying the 7,000,000 shares by the average of the closing bid price of our common stock during the ten trading days preceding the date of the Agreement.  The 512,665 shares in Langley received as consideration was calculated by dividing the total sales price by the conversion rate of the British Pound Sterling to the U.S. dollar as of the close of business on July 26, 2004.  Upon the closing of this transaction, Langley and we were required to issue our respective shares into an escrow account, whereby we could immediately liquidate up to 50% of the Langley shares. We and the other portfolio companies have received one-half of the free-trading Langley ordinary shares sold to us under the Stock Purchase Agreement. The remaining 50% of the free-trading Langley ordinary shares will be held in escrow for two years as a downside price protection against our shares issued to Langley.  In the event of a decline in the market price of our common stock at the end of two years, we will be required to sell to Langley the amount of our Langley shares equal to (i) the original number of Langley shares issued as consideration under the Stock Purchase Agreement multiplied by (ii) the percentage decrease in the market price of our common stock.  If at the end of the two-year period the trading price of our common stock falls below $0.065, we will have to sell back to Langley all the escrowed Langley shares.  If at the end of the trading period the trading price of our common stock is more than $0.065 but less than $0.13, we will need to sell back to Langley only a proportionate amount of our Langley ordinary shares. We have no obligation to register for resale our shares that are held by Langley.



On August 6, 2006, Langley had a net asset value for its underlying portfolio of U.K. $0.28 per ordinary share, or an aggregate net asset value of U.K. $20,881,511 (U.S. $39,496,491, based on U.K. $1.00 = U.S. $1.891 on August 10, 2006).  Assuming that the downside protection (or "claw-back rights") had been exercised by Langley, this would represent a net asset value per ordinary share of U.K. $0.18, or an aggregate net asset value of U.K.$13,423,829 (U.S. $25,394,361).  We had anticipated that the trust would traditionally trade at a discount to its net asset value; however, the discount has been more significant than we expected.  To date, due to the low trading price of the Langley stock on the London Stock Exchange (U.K. $0.12 per ordinary share on August 10, 2006), we have not sold any of our Langley ordinary shares.



The rights of holders of Langley ordinary shares are set forth in Langley's Memorandum of Association. In general, each holder of Langley ordinary shares has one vote for every ordinary share held. Unless Langley's directors decide otherwise, a holder of ordinary shares may not vote, either personally or by
proxy, unless all calls and other amounts payable with respect to the ordinary shares have been paid. Holders of ordinary shares may receive dividends in Langley as and when declared by the directors. In the event of a liquidation of Langley, holders of ordinary shares may receive their pro rata share of any remaining assets. In the event that Langley has more than one class of shares, the rights of the holders of any one class of shares may be varied only with the written consent of holders of three-fourths of the nominal value of the issued shares of that class, or with the sanction of an extraordinary resolution passed at a separate general meeting of such holders.



We considered a variety of possible financing options prior to entering into the transaction with Langley. In the past year, it has become more difficult for us to effect equity placements on terms and conditions satisfactory to us and our shareholders.  We were approached by a number of private investors who sought to purchase common stock at significant discounts to market and other potential investors who wanted to receive common stock in advance of forwarding consideration for the stock to us. None of these alternatives were acceptable to management. We selected Langley after due diligence on Langley and its management, including but not limited to a review of a prior fund with similar structure and investment strategies, assembled by the founders of Langley.



8

Effective October 28, 2004, we entered into a loan agreement (the "Loan Agreement") with Pini Ben David (Grunspan), an individual who lives in Switzerland ("Ben David"). Ben David is not, and has not been during the past two years, an affiliate of us or any of our current or former affiliates. The Loan Agreement called for Ben David to loan us an aggregate of € 2,300,000 euros (the "Loan"). The Loan was to bear interest at the rate of three percent per annum, with payments of interest due monthly and all principal plus accrued but unpaid interest due and payable on November 1, 2007. Repayment of the Loan was secured by 23,000,000 shares of our common stock (the "Shares") issuable pursuant to Regulation S under the Securities Act. Pursuant to the Loan Agreement and an Escrow Agreement between Ben David and us, a certificate representing the Shares (the "Certificate"), containing a legend restricting transfer, was delivered to Ben David to hold until funds for repayment of the Loan were delivered to the escrow agent. We believe that the parties intended that when the loan funds were delivered by Ben David to the escrow agent, Ben David would also deliver the stock certificate to the escrow agent, who would disburse the funds and the certificates to the appropriate parties. The Loan Agreement also provided that it would terminate, and the Shares immediately returned to us, in the event that the Loan funds were not delivered to us by the 15th calendar day following the date of the Loan Agreement (November 13, 2004). Pursuant to Ben David's request, we extended the date for receipt of Loan funds to December 23, 2004 and exchanged the certificate for three certificates (one to Ben David and one to each of two affiliates); however, no Loan funds were received by that date. On January 11, 2005, we instructed our transfer agent to cancel the Certificates, and notified Ben David that the Loan Agreement was cancelled and of no further force or effect. We did not incur any early termination penalties in connection with the cancellation of the Loan Agreement.



In the second quarter of 2005, it came to our attention that shares of our common stock (the "Reg S Stock") may have been sold in Germany without our authorization, possibly in connection with the canceled Ben David certificates in order to halt these unauthorized issuances, we commenced an exchange offer (the Offer) in July 2005 to exchange one share of our common stock (the "New Stock") for each share of Reg S Stock outstanding before or upon the delisting date (the "Record Date") when the Reg S Stock is no longer tradable. The Offer covered an aggregate of 10,000,000 shares of our common stock, and was intended to reduce potential liability for the unauthorized issuances.  Holders of an aggregate of 9,591,592 shares of the Reg S stock forwarded certificates and required documents, leaving an aggregate of 408,408 shares outstanding.  On June 15, 2006, the registration statement for these shares of New Stock was declared effective by the Securities and Exchange Commission.



In March 2005, we entered into an agreement with Abernathy (which was subsequently amended in April 2005).  The Abernathy agreement provided that Abernathy would promote us to the investment community and the general public through press releases and other communications, all of which we must approve in advance.  The term of the Abernathy agreement was six months, subject to prior termination.  In consideration for the public relations services, we were required to issue compensation shares to Abernathy equal to 30% of the increase in buy volume of our common stock that was directly attributable to Abernathy. In addition, we were required to issue bonus shares to Abernathy equal to 10% of the increase in buy volume in the event that the sales price of our common stock as quoted on the NASD OTC Bulletin Board equaled or exceeded $0.25 per share.  We were required to place an aggregate of 3,000,000 free trading shares of common stock in escrow in advance of the services under the Abernathy agreement. Through June 30, 2006, we had issued all of these shares of common stock to Abernathy.



In June 2005, we entered into a second agreement with Abernathy for additional public relations consulting services and issued an additional 750,000 shares of free trading shares of common stock for these services, valued at $247,500. We also became obligated to issue an additional 899,500 shares to Abernathy as a bonus under this second agreement.  These shares will be issued at a future date.



In November 2005, we entered into a third public relations consulting agreement with Abernathy for a term of three months and issued an additional 500,000 shares of free trading common stock in consideration of these services.  The services were valued at $345,000.   In addition, we are required to issue bonus shares to Abernathy equal to 20% of the increase in trade volume in excess of 100,000 shares (exclusive of shares traded on any exchange other than the NASD OTC Bulletin Board) after the initial five days of the agreement.   Through December 31, 2005, we released 4,963,600 shares of common stock totaling $3,125,200 in consideration of these agreements.  Additionally, we recorded a public relations payable for approximately 219,400 additional compensation and bonus shares to be released at a future date, valued at $187,900. During the six months ended June 30, 2006, 201,100 shares valued at $134,000 were released in satisfaction of this payable.



In October 2005, we entered into an agreement with Ascendiant Securities, LLC ("Ascendiant") providing that Ascendiant would act on a best-efforts basis as our financial advisor and non-exclusive placement agent in connection with the structuring, issuance and sale of our debt and equity securities for financing purposes.  The agreement, which has a term of six months, requires us to pay Ascendiant a cash success fee and warrants for completed transactions that we approve.  The success fee is equal to ten percent of the gross proceeds from the sale of our securities; in addition, for transactions generating gross proceeds of $2,000,000 or more, we must issue Ascendiant 175,000 shares of our restricted common stock.  To date, no transactions have been presented to us by Ascendiant.



In March 2006, we entered into a loan agreement with an independent lender.  The lender agreed to loan us an amount based on 50% of the value of a portfolio of 500,000 shares of our common stock (approximately $90,000).  These shares are held as collateral only. The lender will receive a loan fee equal to five percent of the gross loan proceeds.  We received net funds in the amount of $71,250, which was based on a formula and pricing period following the agreement date. The agreement calls for interest payment of 4.99% annual rate of the loan amount payable quarterly for period three years. At maturity, we have the option to pay off the loan balance and receive the same number of shares pledged, sell the pledged shares under certain conditions or renew the loan under certain conditions, or forfeit the shares and not repay the loan.



9

In March 2006, we entered into a Securities Purchase Agreement (the Agreement) with La Jolla Cove Investors, Inc., a California corporation (La Jolla Cove).  Pursuant to the Agreement, La Jolla Cove agreed to purchase from us a 63⁄4% Convertible Debenture in the aggregate principal amount of $30,000 (the Debenture).  Pursuant to the agreement terms, we received $30,000, the purchase price of the debenture.  In connection with the Debenture, we also issued to La Jolla Cove a Warrant to Purchase Common Stock (the Warrant), dated as of March 7, 2006, to purchase an aggregate of 3,000,000 shares of common stock.  Pursuant to the terms of the Warrant, we received $95,000 as a prepayment towards the future exercise of Warrant Shares.



In May 2006, we returned to La Jolla Cove the aggregate advances of $125,000.  Management believed that due to substantially modified terms proposed for the transaction by La Jolla Cove, the parties failed to agree on the material terms and conditions of this proposed transaction.  We and La Jolla Cove subsequently mutually agreed not to pursue this transaction.

We have also registered 20,000,000 shares of our common stock for use in raising capital   To date, we have issued a small number of these shares as consideration for services or debt cancellation.  Other than as set forth, however, we have not entered into any arrangement for the sale of these shares.



Critical Accounting Policies



The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires us to make judgments, assumptions and estimates that affect the amounts reported. Note 1 of Notes to Financial Statements included in our Annual Report on Form 10-KSB for the year ended December 31, 2005, describes the significant accounting policies used in the preparation of the financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.



A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: 1) we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and 2) different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.



Estimates and assumptions about future events and their effects cannot be determined with certainty. We base our estimates on historical experience and on various other assumptions believed to be applicable and reasonable under the circumstances. These estimates may change as new events occur, as additional information is obtained and as our operating environment changes.  These changes have historically been minor and have been included in the consolidated financial statements as soon as they became known. Based on a critical assessment of our accounting policies and the underlying judgments and uncertainties affecting the application of those policies, management believes that our financial statements are fairly stated in accordance with accounting principles generally accepted in the United States, and present a meaningful presentation of our financial condition and results of operations.



In preparing our financial statements to conform to accounting principles generally accepted in the United States, we make estimates and assumptions that affect the amounts reported in our financial statements and accompanying notes. These estimates include useful lives for fixed assets for depreciation calculations and assumptions for valuing options and warrants. Actual results could differ from these estimates.



10

We consider that the following are critical accounting policies:



Research and Development Expenses



All research and development costs are expensed as incurred. The value of acquired in-process research and development is charged to expense on the date of acquisition. Research and development expenses include, but are not limited to, payroll and personnel expense, lab supplies, preclinical studies, raw materials to manufacture our solution, manufacturing costs, consulting, legal fees and research-related overhead. Accrued liabilities for raw materials to manufacture our solution, manufacturing costs and patent legal fees are included in accrued liabilities and included in research and development expenses.



Employee Stock Plans



On January 1, 2006, we adopted Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004), Share-Based Payment, requiring us to recognize expense related to the fair value of its employee stock option awards.  We recognize the cost of all share-based awards on a graded vested basis over the vesting period of the award.
Prior to January 1, 2006, we accounted for our stock option plans under the recognition and measurement provisions of APB Opinion No. 25, Accounting for Stock Issued to Employees, and related Interpretations, as permitted by SFAS No. 123, Accounting for Stock-Based Compensation.  Effective January 1, 2006, we adopted the fair value recognition provisions of SFAS No. 123(R), using the modified-prospective-transition method.  Under that transition method, compensation cost recognized in 2006 includes: (a) compensation cost for all share-based payments granted prior to, but not yet vested as of January 1, 2006, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, and (b) compensation cost for all share-based payments granted subsequent to January 1, 2006, based on the grant-date fair value estimated in accordance with the provisions on SFAS No. 123(R).  Results for prior periods have not been restated.



RISK FACTORS



Investing in our shares is very risky.  You should be able to bear a complete loss of your investment.  In deciding whether to purchase our shares, you should carefully consider the following factors, among others, as well as information contained in this prospectus, our most recent annual report on Form 10-KSB, and the other documents incorporated by reference into this prospectus:



RISK FACTORS RELATED TO OUR COMPANY



Our business, financial condition or results of operations could be materially and adversely affected by any of the following risks:



WE HAVE A HISTORY OF LOSSES, AND OUR INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS HAVE RAISED DOUBTS ABOUT OUR ABILITY TO CONTINUE AS A GOING CONCERN.



Since our inception in 1998, we have incurred substantial losses from operations, resulting primarily from costs related to research and development and building our infrastructure.  Because of our status as a development stage company and the need to conduct additional research and development prior to introducing products and services to the market, we expect to incur net losses for the foreseeable future.  If our growth is slower than we anticipate or our operating expenses exceed our expectations, our losses will be significantly greater.  We may never achieve profitability.  Primarily as a result of these recurring losses, our independent certified public accountants have modified their report on our December 31, 2005 financial statements to include an uncertainty paragraph wherein they expressed substantial doubt about our ability to continue as a going concern.



We are in the ninth year of research and development, with an accumulated loss during the development stage (through June 30, 2006) of $21,820,600.  We currently do not know when our research and development will be completed, or if a product will ever result from this research and development activity.  We anticipate that the funds spent on research and development activities will need to increase significantly prior to completion of research and development and commercialization of a product.  Additionally, we may not be able to secure funding in the future necessary to complete our intended research and development activities.  In 2003, we scaled back our research and development activities significantly, due to our lack of capital.  In February 2005, we resumed certain research and development projects on a limited basis, but cannot predict when we will be able to maintain a complete research and development program.



These conditions give rise to substantial doubt about our ability to continue as a going concern. Our financial statements do not include adjustments relating to the recoverability and classification of reported asset amounts or the amount and classification of liabilities that might be necessary should we be unable to continue as a going concern.  Our continuation as a going concern is dependent upon our ability to obtain additional financing from the sale of our securities, as may be required, and ultimately to attain profitability.



WE REQUIRE IMMEDIATE ADDITIONAL CAPITAL.



Our operating plan for calendar years 2006 and 2005 is focused on development of our products. It is our estimate that a cash requirement of $2.5 million is required to support this plan for the next twelve months.  During the six-month period ended June 30, 2006, we received an aggregate of $724,400 from the issuance of common stock and $75,000 from borrowing on notes payable, compared to an aggregate of $552,700 received in the six-month period ended June 30, 2005.  We are actively seeking additional funding. There can be no assurance that the required additional financing will be available on terms favorable to us or at all. Although we have entered into certain agreements with Dutchess and other prospective funding sources, there can be no assurance that we will be successful in raising any additional capital pursuant to the Dutchess agreement or these other agreements.



11

Obtaining capital will be challenging in a difficult environment, due to the slow recovery from the downturn in the United States economy and current world instability. We currently have commitments for any funding; however there can be no assurance that we will be able to obtain additional funding in the future from either debt or equity financings, bank loans, collaborative arrangements or other sources on terms acceptable to us, or at all. If our human infusion studies are successful, we believe that we will be able to obtain additional funding through a license agreement with one or more of the potential strategic partners with whom we have had discussions to date, thereby satisfying our financial needs for at least 2006; however, we currently do not have the capital to complete our infusion studies and there can be no assurance that we will achieve successful results in our human infusion studies or that we can enter into a license agreement or agreements providing adequate financing for 2006 and beyond.



If adequate funds are not available or are not available on acceptable terms when required, we may be required to significantly curtail our operations or may not be able to fund expansion, take advantage of unanticipated acquisition opportunities, develop or enhance services or products or respond to competitive pressures. Such inability could have a material adverse effect on our business, results of operations and financial condition.  If additional funds are raised through the issuance of equity or convertible debt securities, the percentage ownership of our shareholders will be reduced, shareholders may experience additional dilution, and such securities may have rights, preferences and privileges senior to those of our common stock.



WE AND OUR CHIEF EXECUTIVE OFFICER ARE THE SUBJECT OF SEC AND JUSTICE DEPARTMENT PROCEEDINGS FOR SECURITIES FRAUD.



On August 7, 2002, the United States Attorney for the Eastern District of New York and the Securities and Exchange Commission announced that they were bringing securities fraud charges against Harry Masuda, our Chief Executive Officer, for allegedly paying an unregistered broker an undisclosed commission in September 1999 and February 2000 private placements. The allegations generally charge Mr. Masuda with the failure to adequately disclose to investors in this private placement a commission agreement with Larry Bryant, an unlicensed broker-dealer. Remedies sought in these proceedings include criminal penalties and a bar from service as an officer or director of a publicly-traded company. The SEC also brought securities fraud charges against us for the same transactions, and these charges are still pending.



In June 2000, we undertook a rescission offer to those shareholders who had purchased an aggregate of 427,300 shares of common stock and warrants in the private placements for aggregate proceeds of $640,950. Holders of 222,900 shares of common stock accepted the rescission offer. The other shareholders elected not to rescind their stock purchases.  We paid an aggregate of approximately $300,000 in cash to rescinding shareholders, but could not afford to pay the balance of the rescission offer in cash. Instead, we issued promissory notes, with interest at the rate of 10% per annum, payable upon the earlier of (i) one year from the date of the note or (ii) our receipt of funding sufficient to permit repayment of the principal and interest on the notes.  In 2000 and 2001, holders of $67,500 in principal and interest in the above-referenced promissory notes elected to convert their notes to an aggregate of 206,700 shares of our common stock. The other rescinding holders were paid in full in cash prior to December 31, 2002. As all of the shareholders electing to rescind have now been paid in full (whether in cash or in shares of common stock), we believe that the issues raised by the alleged failure to disclose have been fully resolved. Although we believe that the charges are unwarranted, there can be no assurance that Mr. Masuda will be able to continue to serve as our Chief Executive Officer in the event that the Securities and Exchange Commission receives the remedies that it seeks. In January 2005, the United States Government and Mr. Masuda entered into a deferred prosecution agreement which led to a dismissal of all charges against Mr. Masuda at the end of the 18-month deferred prosecution term in July 2006. The civil case against us has been stayed at the request of the U.S. Attorney pending completion of the deferred prosecution term.



WE ARE A DEVELOPMENT STAGE COMPANY, AND HAVE A LIMITED OPERATING HISTORY ON WHICH TO EVALUATE OUR POTENTIAL FOR FUTURE SUCCESS.



We are a development stage company, and have yet to produce or sell any products or services.  We have only a limited operating history upon which you can evaluate our business and prospects, and have yet to develop sufficient experience regarding actual revenues to be received from our products and services.  You must consider the risks and uncertainties frequently encountered by early stage companies in new and rapidly evolving markets.  If we are unsuccessful in addressing these risks and uncertainties, our business, results of operations and financial condition will be materially and adversely affected.



12

OUR FUTURE REVENUES ARE UNPREDICTABLE AND OUR QUARTERLY OPERATING RESULTS MAY FLUCTUATE SIGNIFICANTLY.



We have a very limited operating history, and have no revenue to date. We cannot forecast with any degree of certainty whether any of our products or services will ever generate revenue or the amount of revenue to be generated by any of our products or services. In addition, we cannot predict the consistency of our quarterly operating results. Factors which may cause our operating results to fluctuate significantly from quarter to quarter include:



-  our ability to attract new and repeat customers;



-  our ability to keep current  with  the evolving requirements of our target market;



-  our ability to protect our proprietary technology;



-  the ability of our  competitors to offer new or enhanced products or  services; and



-  unanticipated  delays or cost  increases  with  respect to research and development.



Because of these and other factors, we believe that quarter-to-quarter comparisons of our results of operations are not good indicators of our future performance.  If our operating results fall below the expectations of securities analysts and investors in some future periods, then our stock price may decline.



ESTABLISHING OUR REVENUES AND ACHIEVING PROFITABILITY WILL DEPEND ON OUR ABILITY TO DEVELOP AND COMMERCIALIZE OUR PRODUCTS.



Much of our ability to establish revenues and to achieve profitability and positive cash flows from operations will depend on the successful introduction of our products in development.  Products based on our technologies will represent new methods of treatment and preservation. Our prospective customers, including blood banks, hospitals and clinics, will not use our products unless they determine that the benefits provided by these products are greater than those available from competing products.  Even if the
>advantage from our planned products is clinically established, prospective customers may not elect to use such products for a variety of reasons.



We may be required to undertake time-consuming and costly development activities and seek regulatory clearance or approval for new products. The completion of the development and commercialization of any of our products under development remains subject to all of the risks associated with the commercialization of new products based on innovative technologies, including unanticipated technical or other problems, manufacturing difficulties and the possible insufficiency of the funds allocated for the completion of such development.



WE MAY NOT BE ABLE TO COMPETE SUCCESSFULLY.



As a development stage company, we are entering a biological material preservation market that is presently addressed by large companies with extensive financial resources.  Those companies include DuPont and Baxter, among others.  Additionally, smaller companies with which we may compete include LifeCell Corporation for platelet preservation, Cerus for viral inactivation of platelets and other blood products and Cryo Life for preserving heart valves by cryo-preservation. These companies are active in research and development of biological material preservation.  We have limited funds with which to develop products and services.  These companies are active in research and development of biological material preservation, and we do not know the current status of their development efforts.  We have limited funds with which to develop products and services, and most of the above competitors have significantly greater financial resources, technical expertise and managerial capabilities than we currently possess.



13

WE MAY FAIL TO OBTAIN GOVERNMENT APPROVAL OF OUR PROCESSES.



The FDA regulates the commercial distribution and marketability of medical solutions and equipment.  In the event that we determine that these regulations apply to our proposed products, we will need to obtain FDA approval for such distribution.  The process of obtaining FDA approval may be expensive, lengthy and unpredictable.  We have not developed our products to the level where these approval processes can be started.  We do not know if such approval could be obtained in a timely fashion, if at all.  In the event that we do not receive any required FDA approval for certain products, we would not be able to sell such products in the United States.



The regulation of our processes and products outside the United States will vary by country. Noncompliance with foreign country requirements may include some or all of the risks associated with noncompliance with FDA regulation as well as other risks.



ACTS OF TERRORISM, RESPONSES TO ACTS OF TERRORISM AND ACTS OF WAR MAY IMPACT OUR BUSINESS AND OUR ABILITY TO RAISE CAPITAL.



Future acts of war or terrorism, national or international responses to such acts, and measures taken to prevent such acts may harm our ability to raise capital or our ability to operate, especially to the extent we depend upon activities conducted in foreign countries, such as Russia where we currently maintain a branch office.  In addition, the threat of future terrorist acts or acts of war may have effects on the general economy or on our business that are difficult to predict.  We are not insured against damage or interruption of our business caused by terrorist acts or acts of war.



WE MAY FAIL TO ESTABLISH AND MAINTAIN STRATEGIC RELATIONSHIPS.



We believe that the establishment of strategic partnerships will greatly benefit the growth of our business, and we intend to seek out and enter into strategic alliances.  We may not be able to enter into these strategic partnerships on commercially reasonable terms, or at all.  Even if we enter into strategic alliances, our partners may not attract significant numbers of customers or otherwise prove advantageous to our business.



Our inability to enter into new distribution relationships or strategic alliances could have a material and adverse effect on our business.



RISK FACTORS RELATED TO OUR STOCK PRICE



SHARES ELIGIBLE FOR FUTURE SALE BY OUR CURRENT SHAREHOLDERS MAY ADVERSELY AFFECT OUR STOCK PRICE.



To date, we have had a very limited trading volume in our common stock.  As long as this condition continues, the sale of a significant number of shares of common stock at any particular time could be difficult to achieve at the market prices prevailing immediately before such shares are offered.  In addition, sales of substantial amounts of common stock, including shares issued upon the exercise of outstanding options and warrants, under Securities and Exchange Commission Rule 144 or otherwise could adversely affect the prevailing market price of our common stock and could impair our ability to raise capital at that time through the sale of our securities.  A number of our employees and consultants have elected to convert a portion of their compensation to shares of our common stock, and these shares have been registered for resale to the public.



14

OUR COMMON STOCK PRICE IS LIKELY TO BE HIGHLY VOLATILE; OUR COMMON STOCK IS PENNY STOCK.



The market price of our common stock is likely to be highly volatile as the stock market in general, and the market for technology companies in particular, has been highly volatile.  The trading prices of many technology companies' stocks have recently been highly volatile and have recorded lows well below historical highs.



Factors that could cause such volatility in our common stock may include, among other things:



-  actual  or  anticipated fluctuations in our quarterly operating results;



-  announcements of  technological  innovations;



-  changes  in  financial  estimates  by  securities  analysts;



-  conditions  or  trends  in our industry;  and



-  changes  in  the  market  valuations  of  other comparable companies.



In addition, our stock is currently traded on the NASD OTC Bulletin Board and it is uncertain that we will be able to successfully apply for listing on the AMEX, the NASDAQ National Market, or the NASDAQ SmallCap Market in the foreseeable future due to the trading price of our common stock, our working capital and revenue history.  Failure to list our shares on the AMEX, the NASDAQ National Market, or the NASDAQ SmallCap Market will impair the liquidity of our common stock.



The Securities and Exchange Commission has adopted regulations which generally define a "penny stock" to be any security that 1) is priced under five dollars, 2) is not traded on a national stock exchange or on NASDAQ, 3) may be listed in the "pink sheets" or the NASD OTC Bulletin Board, and 4) is issued by a company that has less than $5 million in net tangible assets and has been in business less than three years, or by a company that has under $2 million in net tangible assets and has been in business for at least three years, or by a company that has revenues of less than $6 million for three years.



Penny stocks can be very risky, as they are low-priced shares of small companies not traded on an exchange or quoted on NASDAQ.  Prices often are not available. Investors in penny stocks are often unable to sell stock back to the dealer that sold them the stock.  Thus, an investor may lose his/her investment.



15

Our common stock is a penny stock and thus is subject to rules that impose additional sales practice requirements on broker/dealers who sell such securities to persons other than established customers and accredited investors, unless the common stock is listed on the NASDAQ SmallCap Market. Consequently, the penny stock rules may restrict the ability of broker/dealers to sell our securities, and may adversely affect the ability of holders of our common stock to resell their shares in the secondary market.



SOME OF THE INFORMATION IN THIS QUARTERLY REPORT CONTAINS FORWARD-LOOKING STATEMENTS.



Some of the information in this Quarterly Report contains forward-looking statements that involve substantial risks and uncertainties.  You can identify these statements by forward-looking words such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words.  You should read statements that contain these words carefully because they:



-     discuss our expectations about our future performance;



-     contain projections of our future operating results or of our future financial condition; or



-     state other "forward-looking" information.



We believe it is important to communicate our expectations to our shareholders.  There may be events in the future, however, that we are not able to predict accurately or over which we have no control.  The risk factors listed in this section, as well as any cautionary language in this Quarterly Report, provide examples of risks, uncertainties and events that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements.



ITEM 3.  CONTROLS AND PROCEDURES



Based on an evaluation conducted within 90 days prior to the filing date of this Quarterly Report on Form 10-QSB, our Chief Executive Officer and acting Chief Financial Officer concluded that we maintain effective disclosure controls and procedures that ensure information required to be disclosed in our reports under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.  Specifically, the disclosure controls and procedures assure that information is accumulated and communicated to our management, including our Chief Executive Officer and acting Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.  There have been no significant changes in our internal controls or in other factors that could significantly affect these controls subsequent to the date of management's evaluation.





PART II -- OTHER INFORMATION



ITEM 1.  LEGAL PROCEEDINGS.



In January 2005, the United States Government and Harry Masuda, our Chief Executive Officer, entered into a deferred prosecution agreement calling for the dismissal of all charges against Mr. Masuda at the end of an 18-month deferred prosecution term   Such term expired, and the charges were dismissed, in July 2006.



ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.



Set forth in chronological order is information regarding shares of common stock issued and options and warrants and other convertible securities granted by us during the three months ended June 30, 2006.  Also included is the consideration, if any, received by us for such shares, options and warrants, and information
relating to the section of the Securities Act of 1933, as amended (the "Securities Act"), or the rule of the Securities and Exchange Commission, under which an exemption from registration was claimed.



In the second quarter of 2006, we issued an aggregate of 568,548 shares of common stock to investors in consideration for public relations services.  The issuances were made in reliance on Section 4(2) of the Act and were made without general solicitation or advertising.  The recipients were sophisticated investors with access to all relevant information necessary to evaluate the investments, who represented to us that the shares were being acquired for investment purposes.



In the second quarter of 2006, we issued an aggregate of 8,237 shares of common stock to an investor in consideration for accounting and financial services.  The issuance was made in reliance on Section 4(2) of the Act and was made without general solicitation or advertising.  The recipient was a sophisticated investor with access to all relevant information necessary to evaluate the investments, who represented to us that the shares were being acquired for investment purposes.



16

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES.



Not applicable.



ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.



Not applicable.



ITEM 5.  OTHER INFORMATION.



Not applicable.



ITEM 6.  EXHIBITS.



|              |                                     
|------------- | ------------------------------------
|Exhibit No.   | Description                         
|------------- | ------------                        
|31.01         | Rule 13a-14(a)/15d-14a Certification
|              |                                     
|32.01         | Section 1350 Certification          





SIGNATURES



In accordance with the requirements of the Exchange Act, the registrant caused this amended report to be signed on its behalf by the undersigned thereunto duly authorized.



|                                                          
|----------------------------------------------------------
|HUMAN BIOSYSTEMS                                          
|                                                          
|Date: August 11 , 2006                                    
|                                                          
|/s/ Harry Masuda                                          
|Harry Masuda                                              
|Chief Executive Officer and Acting Chief Financial Officer





17